ArticleThe Journal of physiology2026
Hyperglycaemia-induced reactive oxygen species production in cardiac ventricular myocytes differs among mammals.
Article in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cardiac regulatory mechanisms: Translating fundamental discoveries into novel therapeutics.The Journal of physiology · 2026Article
- SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.International journal of molecular sciences · 2026Article
- Next-Generation Metabolic Reprogramming in iPSC-Derived Cardiomyocytes: CRISPR-EV Synergy for Precision Cardiac Regeneration.Biomolecules · 2026Review
- Anisotropic Micro/Nanotopography Regulating Mitochondrial Dynamics in Cardiomyocytes.Research (Washington, D.C.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiabetic cardiomyopathy (DbCM) preclinical studies have used animal models from different species and implicated altered redox regulation and reactive oxygen species (ROS) in this disease. However hyperglycaemia-induced ROS signalling may differ in ventricular myocytes from different species, and here we compare mice, rats, rabbits and humans with respect to hyperglycaemia-induced ROS production.
methodsUsing the chemical sensor H
resultsConsistent with our prior mouse studies, HiGlu exposure in rat and human ventricular myocytes increased cytosolic (not mitochondrial) ROS production via a mechanism involving Ca-calmodulin-dependent protein kinase (CaMKII) O-GlcNAcylation (at Ser280) and NADPH oxidase 2 (NOX2) activation. However in rabbit ventricular myocytes HiGlu alone did not induce significant ROS production, unless complemented by low levels of angiotensin II and inhibition of the enzyme that reverses O-GlcNAcylation using 100 nM Thiamet G, where both cytosolic and mitochondrial ROS accumulation were involved by more complex signalling networks.
conclusionAcute hyperglycaemia readily induces robust ROS production in mouse, rat and human ventricular myocytes, but rabbit myocytes are intrinsically better protected from this HiGlu-induced ROS responses. In most regards rabbit are much more human-like than rodents for many aspects of myocyte function, but this surprisingly is not the case for HiGlu-induced ROS production. KEY POINTS: In mouse ventricular myocytes we previously showed that acute hyperglycaemia (HiGlu) induced increase in reactive oxygen species (ROS) mediated by O-GlcNAcylation of Ca-calmodulin-dependent protein kinase at Ser280 and consequent NADPH oxidase 2 (NOX2) activation. Here we demonstrate that this same pathway is functional in human and rat ventricular myocytes but not in rabbit ventricular myocytes. In rat and human myocytes HiGlu induced an increase in cytosolic, but not mitochondrial, ROS production. In rabbit myocytes HiGlu only produced increased ROS (cytosolic and mitochondrial) only when it was accompanied by both low concentration angiotensin II and an O-GlcNAcylase inhibitor (that individually did not promote ROS production). This direct HiGlu-induced ROS production in cardiac myocytes may contribute to pathological signalling in diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.